Temperature excursion in clinical trials: What to do when IP storage conditions are breached: A practical guide for investigators and site pharmacists
The alarm goes off. The site refrigerator storing your investigational product has deviated from its required temperature range. It may have been a brief blip overnight, or it may have been a sustained excursion during a weekend when the site was closed. Whatever the cause, your next actions will be scrutinized during any future audit or regulatory inspection, and they will directly affect whether your participants can continue to receive treatment and whether your trial data remains credible.
Who is this guide for? This guide was written specifically for investigators, study coordinators, and site pharmacists who need a clear, practical, and GCP-compliant reference for what to do when a temperature excursion in clinical trials occurs at their site. It covers the regulatory framework, standard temperature ranges, the seven-step management protocol, documentation requirements, the question of whether affected IP can be used, and practical prevention strategies. Understanding this topic thoroughly is also an important part of any Good Clinical Practice training program designed for site-level professionals, and a recurring subject in ICH GCP certification assessments.
A temperature excursion in clinical trials is one of the most common yet most mismanaged situations at the investigator site level. Site teams often either panic and discard product they could have used, or make the opposite mistake, continuing to administer IP that has been formally compromised, without ever consulting the sponsor or reviewing the available stability data. Both errors have consequences: wasted drug supply, delayed participant dosing, protocol deviations, and, in the worst case, risks to participant safety.
Table of Contents
What is a temperature excursion in clinical trials?
A temperature excursion in clinical trials is defined as any deviation of the investigational product storage conditions outside the temperature range specified in the clinical trial protocol, the investigator’s brochure, or the product label. This deviation may occur at any point in the IP lifecycle at the site level: upon receipt of the shipment, during ongoing storage, during preparation, or during transport between sub-sites.
The terms “temperature excursion” and “temperature deviation” are often used interchangeably in clinical research settings, although some sponsors use them with slightly different nuances. A temperature deviation is the broader term and encompasses any departure from specified conditions, while a temperature excursion specifically implies a measurable and documented out-of-range event. For this guide, we use “temperature excursion” as the primary term throughout.
A temperature excursion in clinical trials is not inherently the same as a protocol deviation, although it frequently becomes one. Whether an excursion constitutes a reportable protocol deviation depends on the severity and duration of the excursion, the product’s stability profile, and the sponsor’s determination following a formal impact assessment. That determination cannot be made unilaterally by the site.
ICH GCP requirements for investigational product storage
The management of investigational product storage conditions is a direct responsibility of the investigator under ICH GCP. The current version of the guideline, ICH E6 R3, which came into effect in January 2025, is explicit on this point: the investigator must ensure that the IP is used only in accordance with the approved protocol and that it is stored according to the conditions specified by the sponsor.
Specifically, ICH E6 R3 requires the following:
- The IP is stored according to the conditions specified by the sponsor and in accordance with applicable regulatory requirements.
- Storage conditions are monitored continuously, and records are maintained.
- The investigator promptly informs the sponsor of any deviation in storage conditions and takes corrective action.
- IP that has been stored under improper conditions is not administered to participants until the sponsor has confirmed its acceptability.
These requirements are binding. An investigator who continues to administer IP after a temperature excursion without first obtaining sponsor approval is in direct violation of ICH GCP E6 R3, regardless of their personal assessment of the product’s integrity. For site staff who want to deepen their understanding of these obligations in context, the ICH GCP E6 R3 Good Clinical Practice training for investigators and site personnel from PharmaEduCenter covers investigational product management in full as part of a comprehensive site-level curriculum.
Understanding these GCP requirements is also a central component of Good Clinical Practice certification exams, in which scenarios involving temperature excursion in clinical trials are frequently tested.
Standard IP temperature ranges: what your protocol should specify
Before you can identify a temperature excursion in clinical trials, your site team must be familiar with the specific storage requirements for every investigational product held at the site. These requirements are defined in the clinical trial protocol and, in more detail, in the investigator’s brochure and on the product label or accompanying documentation.
Although exact specifications vary by product, internationally harmonized guidelines, primarily ICH Q1A and the applicable United States Pharmacopeia chapters, define the following standard storage categories:
Controlled room temperature storage requires maintaining 15°C to 25°C (with excursions typically permitted up to 30°C for short periods, depending on the product). This applies to most tablets, capsules, and oral solid forms that are stable at ambient conditions.
Refrigerated storage requires maintaining a temperature between 2°C and 8°C. This applies to many biologics, monoclonal antibodies, vaccines, and certain liquid formulations. This is the storage range most commonly implicated in temperature excursion in clinical trials because it requires active refrigeration equipment that can fail.
Frozen storage at -20°C to -10°C is required for samples and products that must be preserved long-term without deep-freezing.
Ultra-low temperature storage at -80°C to -60°C applies to advanced therapy medicinal products, cell and gene therapy products, and certain highly sensitive biologics. A temperature excursion in clinical trials involving ultra-low storage is particularly consequential because these products often have very narrow stability margins.
At every site, the specific required range for each IP stored must be posted clearly on or near the storage unit, incorporated into the site’s standard operating procedures, and confirmed in writing at site initiation. The site file must contain documented evidence that the storage equipment in use has been validated or qualified to maintain the required range.
Common causes of temperature excursion at clinical sites
Understanding why temperature excursions in clinical trials happen is the first step toward preventing them. The most frequently observed causes at the site level include:
- Equipment failure is the most unpredictable cause. Refrigerators and freezers have finite lifespans, compressors can fail without warning, and power fluctuations can interrupt operation. A unit that passed its last calibration may still fail six months later. This is why continuous automated monitoring is not optional; it is a GCP requirement.
- Power interruptions may be brief or sustained. Overnight power cuts due to storms, planned maintenance, or grid failures can expose refrigerated IP to progressive temperature rise. Sites in regions with unreliable power infrastructure must have documented contingency plans, including qualified backup storage.
- Human error accounts for a significant proportion of temperature excursions in clinical trials at the site level. Doors left ajar, products placed too close to the cooling element, causing freeze damage, or products placed in the wrong unit are all preventable with adequate Good Clinical Practice training and robust site SOPs.
- Shipping and receipt issues occur when IP arrives at the site already having experienced a temperature excursion during transit. The shipper’s temperature data logger records the excursion, but the site does not always review it systematically at receipt. If this data is not checked, the site may store and later administer a compromised product.
- Seasonal and environmental factors can cause ambient conditions at the site to affect storage equipment performance, particularly in facilities without climate control, during heat waves, or in regions with extreme seasonal temperature variation.
7 steps to manage a temperature excursion in clinical trials
When a temperature excursion in clinical trials occurs at your site, every step must be systematic, contemporaneous, and fully documented. The following protocol reflects GCP requirements and is aligned with Good Documentation Practice principles, including the ALCOA+ standard (attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, and available).
Step 1: Detect and document immediately
As soon as a temperature excursion is identified, whether by an automated alarm, a manual temperature log review, or a monitoring report, the date, time, current temperature, and duration of the excursion must be recorded. If your monitoring system produces an automated report, print or save it immediately and attach it to your excursion record. The record must be created contemporaneously; retrospective reconstruction of timelines is a serious data integrity issue and a significant finding during GCP inspections.
Step 2: Quarantine the affected IP
All investigational products that were stored in the affected unit during the excursion period must be immediately quarantined. This means physically segregating the product from stock that remains available for use and labeling it clearly as “Quarantined, pending impact assessment” or equivalent. Quarantined IP must not be dispensed, administered, or discarded until a formal usability determination has been received from the sponsor or their designated representative.
Step 3: Notify the sponsor without delay
The investigator’s first communication obligation in the event of a temperature excursion in clinical trials is to notify the sponsor. Most protocols define specific timelines for this notification, commonly within 24 to 48 hours of discovery, and often sooner for critical products. The notification should include: the date and time of discovery, the estimated duration of the excursion, the minimum and maximum temperatures recorded, the quantity and batch numbers of affected product, and any preliminary information about the cause.
Do not wait until you have resolved the situation before notifying the sponsor. The sponsor or their pharmacovigilance team needs the information early so they can initiate the stability assessment.
Step 4: Conduct a stability impact assessment in collaboration with the sponsor
The sponsor, typically through their quality assurance or analytical development team, will conduct a formal stability impact assessment. This assessment compares the actual excursion parameters (temperature range, duration, cumulative excursion time) against the product’s existing stability data to determine whether the IP remains within acceptable quality limits.
Some protocols pre-define allowable excursion limits, for example, specifying that the product may tolerate up to 24 hours between 8°C and 15°C without loss of potency. Others require a case-by-case assessment for every excursion, regardless of duration. The site’s role at this stage is to provide accurate and complete excursion data and to cooperate promptly with any additional information requests from the sponsor.
Step 5: Await the formal usability decision
Under no circumstances should the site make an independent determination about whether the affected IP can be used. The usability decision rests with the sponsor, based on their stability data and quality standards. The site must await written confirmation before taking any action with the quarantined product. If the sponsor determines the product is acceptable for use, that determination must be documented in the site file. If the sponsor determines the product must be destroyed, the destruction must follow the protocol-specified procedure for IP disposal and be fully documented.
Step 6: Implement CAPA
Once the immediate situation has been resolved, the site must implement a Corrective and Preventive Action (CAPA) plan. The CAPA must identify the root cause of the temperature excursion in clinical trials, the corrective actions taken to address the immediate event, and the preventive actions implemented to reduce the risk of recurrence. Common CAPA elements include equipment maintenance or replacement, staff retraining, updated SOPs, enhanced monitoring frequency, or installation of additional backup systems. The CAPA must be documented, tracked to closure, and retained in the site file.
Step 7: Report and close out the deviation
Depending on the outcome of the stability assessment and the sponsor’s determination, the temperature excursion in clinical trials may need to be reported as a protocol deviation. The site must complete the deviation report in the format required by the sponsor, submit it within the timelines specified in the protocol or monitoring plan, and retain all supporting documentation. The deviation must also be disclosed to the IRB or IEC if required by local regulations or if the excursion affected participant safety. Transparency in deviation reporting is a fundamental principle of GCP and is a key competency assessed in ICH GCP certification programs.
What documentation is required after a temperature excursion in clinical trials?
Thorough documentation is the most important output of the temperature excursion management process. The site file must contain, at a minimum:
A completed temperature excursion report or deviation form, including all the elements described in Step 1 above. This should be supported by printouts or exports from the automated temperature monitoring system, clearly showing the timeline of the event.
All sponsor communications related to the excursion, including the initial notification and the written usability determination. If these communications occurred by email, the email chain should be printed and filed.
The IP accountability log must reflect the quarantine status of the affected product, the disposition decision (use or destruction), and, where applicable, the batch replacement process if a substitute product is shipped to the site.
The CAPA document, signed and dated, with evidence of implementation and closure.
Any updated SOPs or training records generated as a result of the CAPA.
This documentation standard is consistent with the Good Documentation Practices framework and with what regulators and auditors expect to find during a site inspection following a known temperature excursion. Incomplete or retrospectively constructed records are among the most serious findings in this context.
Can the IP be used after a temperature excursion in clinical trials?
This is the question that most investigators want answered quickly, and the honest answer is: it depends, but not on your judgment. Whether IP can be used after a temperature excursion in clinical trials is exclusively a sponsor decision, informed by the product’s stability data and the specific parameters of the excursion.
Some products are remarkably resilient. A monoclonal antibody that has been out of refrigeration for two hours at 20°C may be entirely within its stability budget and fully acceptable for continued use. Other products, particularly cell therapies, certain mRNA-based products, or early-phase compounds with limited stability data, may be irreversibly compromised by even a brief excursion.
The concept of the “stability budget” or “remaining stability budget” (RSB) is increasingly used in this context. The stability budget defines the total cumulative excursion time above or below the ideal storage range that the product can withstand before it loses stability. Each excursion reduces the remaining budget. If the remaining stability budget at the time of administration is adequate, the product may be used; if not, it cannot be dispensed. This concept is discussed in detail in the context of clinical supply chain management and is covered in specialist GCP training for site pharmacists and pharmacy staff.
The site must never discard potentially viable product without sponsor authorization, nor must it administer potentially compromised product without written sponsor clearance. Both errors are GCP violations that could result in significant findings during an audit or inspection.
How to prevent temperature excursion at your clinical site
Prevention is always preferable to management. While not every temperature excursion in clinical trials is preventable, the most common causes can be addressed with systematic measures:
Continuous automated temperature monitoring is the baseline requirement. Manual logbooks recorded once or twice daily leave gaps of many hours during which an excursion can occur undetected. Automated systems with calibrated sensors, real-time cloud-based data transmission, and configurable alarm thresholds that alert designated staff immediately when conditions approach or exceed the acceptable range are now standard in well-operated trial sites. Calibration certificates for all monitoring equipment must be current, traceable to national standards, and retained in the site file.
Equipment qualification and preventive maintenance schedules must be in place for all storage units. Refrigerators and freezers used to store investigational product must be qualified for the purpose, and there must be a documented maintenance schedule with records of all servicing, repairs, and temperature map validation.
Contingency planning ensures that when equipment fails, the response is guided by a pre-approved plan rather than improvisation. The site’s IP management SOP should specify the backup storage location, the notification chain, and the maximum acceptable transfer time for each product category stored on site.
Staff training is perhaps the most straightforward yet most frequently neglected preventive measure. Everyone who handles IP at the site, including administrative staff who may be responsible for receiving shipments, must receive documented Good Clinical Practice training that covers storage requirements, monitoring responsibilities, and the escalation procedure for a temperature excursion.
Systematic shipment receipt review means that every IP shipment arriving at the site must be accompanied by temperature data from its transit, and that data must be reviewed and documented at receipt. A shipment that experienced an excursion in transit must be quarantined immediately and the sponsor notified, following the same steps outlined above.
Temperature excursion in clinical trials and GCP inspections
Temperature excursion management is a high-priority area of focus for regulatory inspectors and sponsor auditors alike. Inspectors from the FDA, EMA, and national competent authorities routinely review temperature monitoring records, storage equipment calibration certificates, IP accountability logs, and deviation reports during site inspections.
The most common inspection findings related to temperature excursion in clinical trials include: gaps in temperature monitoring records, missing or out-of-date calibration certificates, absence of written contingency plans, failure to notify the sponsor within the required timeframe, inadequate documentation of the usability decision, administration of product that had not been formally cleared for use following an excursion, and CAPA plans that identify the root cause but do not document evidence of closure.
Sites that are preparing for regulatory inspections should review their temperature excursion history as part of their self-assessment. For a comprehensive guide to audit and inspection readiness at the site level, including IP-specific checklist items, see our ICH GCP audit preparation guide. For investigators wanting to understand the full scope of their obligations, covering everything from site setup to safety reporting, our online course on how to set up a clinical trial site and the Fundamentals of clinical trials provides the foundational knowledge that underpins compliant site operation.
Key takeaways
- A temperature excursion in clinical trials is defined as any deviation of the IP outside its required storage temperature range, whether during storage, transit, or receipt at the site.
- ICH GCP E6 R3 requires that the investigator store IP according to sponsor-specified conditions, monitor those conditions continuously, and notify the sponsor promptly of any excursion.
- Standard IP temperature ranges include controlled room temperature (15–25°C), refrigerated (2–8°C), frozen (-20°C to -10°C), and ultra-low (-80°C to -60°C), with product-specific tolerances defined by the sponsor in the protocol and investigator’s brochure.
- The seven-step management protocol, detect and document, quarantine, notify the sponsor, conduct a stability assessment, await the usability decision, implement CAPA, and close the deviation, must be followed every time a temperature excursion in clinical trials occurs.
- The usability decision rests exclusively with the sponsor. Sites must neither discard potentially viable IP without authorization nor administer potentially compromised IP without written sponsor clearance.
- All documentation must meet ALCOA+ standards: contemporaneous, complete, and accurate records of every action taken are essential for regulatory compliance and data integrity.
- Prevention through continuous automated monitoring, equipment qualification, staff training, and documented contingency planning significantly reduces the frequency and impact of temperature excursions in clinical trials.
Conclusion
A temperature excursion in clinical trials is a serious event that requires a disciplined, structured, and fully documented response. It is not a situation that can be managed informally, resolved with a brief phone call, or dismissed as a minor operational inconvenience. Every excursion has the potential to compromise participant safety, invalidate trial data, and trigger significant findings during GCP inspections, but every excursion also has a right way to be managed that protects the trial, the participants, and the site’s compliance record.
The investigators and site pharmacists who handle these situations most effectively are those who have the foundational knowledge in place before the alarm ever goes off: clear SOPs, a continuous monitoring system, a documented contingency plan, well-trained staff, and an internalized understanding of what GCP requires of them. That knowledge comes from the kind of rigorous, practical GCP training that prepares site professionals not just for certification exams, but for the real situations they will encounter in the clinic.
Adverse event reporting, protocol deviations, and investigational product management, including temperature excursion response, are interconnected areas of site responsibility. For a comprehensive view of how these obligations fit together, see our guide to adverse event reporting in clinical trials and our overview of the principles of ICH GCP.
Are you ready to strengthen your site's GCP knowledge?
Whether you are an investigator who needs to understand your IP management responsibilities in depth, a study coordinator preparing for your first site initiation visit, or a site pharmacist looking to refresh your knowledge of the latest ICH E6 R3 requirements, PharmaEduCenter has the training you need.
Our ICH GCP E6 R3 Good Clinical Practice training for investigators and site personnel covers investigational product storage and temperature excursion management as part of a comprehensive, accredited curriculum designed specifically for those working at the clinical trial site level. Trusted by over 6,000 certified professionals across more than 70 countries, it is the most practical route to Good Clinical Practice certification for site staff who need to learn and apply GCP in their daily work.
Explore our Good Clinical Practice training courses today and ensure that your site is ready, not just for the next temperature alarm, but for every GCP challenge that clinical research brings.
FAQ: Temperature excursion in clinical trials
What is a temperature excursion in clinical trials?
A temperature excursion in clinical trials is any documented deviation of the investigational product outside the temperature range specified in the trial protocol or product labeling, whether during storage, transit, or receipt at the clinical site.
What should I do first if I discover a temperature excursion?
The first two actions are always documentation and quarantine. Document the excursion in real time, recording the date, time, current temperature, and estimated duration, and immediately quarantine all IP that was stored in the affected unit. Do not administer or discard any product until you have notified the sponsor and received a formal usability determination.
Who decides whether the IP can still be used after a temperature excursion?
The sponsor makes the usability determination based on the product’s stability data and the specific parameters of the excursion. The investigator must never make this determination independently.
Does a temperature excursion always need to be reported as a protocol deviation?
Not necessarily. Whether the excursion constitutes a reportable protocol deviation depends on the outcome of the stability assessment and the sponsor’s determination. However, every excursion must be documented internally, communicated to the sponsor, and retained in the site file.
How quickly must I notify the sponsor of a temperature excursion?
Notification timelines are typically defined in the clinical trial protocol or in the site’s monitoring plan. Most sponsors require notification within 24 to 48 hours of discovery, and some require immediate notification for critical products or severe excursions. Always refer to your protocol first, and when in doubt, notify sooner rather than later.
What is a CAPA, and why is it required after a temperature excursion?
A CAPA, Corrective and Preventive Action, is the documented response to the root cause of the excursion. The corrective action addresses the immediate event, and the preventive action implements measures to reduce the risk of recurrence. CAPA documentation is a GCP requirement and is reviewed during audits and inspections.
Is temperature monitoring a GCP requirement at clinical sites?
Yes. ICH GCP E6 R3 requires that the investigator ensure IP is stored according to the conditions specified by the sponsor and that storage conditions are continuously monitored and recorded. Gaps in temperature monitoring records are a frequent inspection finding.
How can I learn more about investigational product management and GCP requirements?
The ICH GCP E6 R3 Good Clinical Practice certification training course from PharmaEduCenter is the most comprehensive resource for clinical trial site professionals seeking to understand their obligations under the current guideline. The Fundamentals of Clinical Trials course is also an excellent starting point for those new to clinical research.
Can an investigator delegate adverse event reporting to a coordinator?
Partially. The administrative aspects of adverse event reporting, completing the SAE form, and entering data into the sponsor’s reporting portal can be delegated to a trained coordinator documented on the delegation of authority log. However, the clinical assessment of an adverse event, determining its seriousness, causality, and classification, must be performed by a qualified physician. The investigator retains overall accountability for all adverse event reporting at the site, regardless of what has been delegated.
What happens if an SAE is not reported within the required timeline?
Late or missed SAE reporting is a GCP violation. It may be flagged as a finding at a monitoring visit or regulatory inspection, classified as a protocol deviation or serious GCP violation depending on severity, and may result in action by the sponsor, including site retraining, increased monitoring frequency, or in serious cases, site suspension. In the most severe cases, where unreported or delayed SAEs are found to have affected participant safety across multiple sites, regulatory authorities may place a clinical hold on the entire study.
